Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06302868 · ClinicalTrials.gov registry record · NA
Telemedicine-Based Virtual Reality Clinic for the Treatment of Phobias
A NA study of Arachnophobia and Cynophobia, sponsored by University of South Florida.
- Recruiting
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT06302868: Recruiting NA study of Arachnophobia and Cynophobia, sponsored by University of South Florida.
NCT06302868 is a NA study of Arachnophobia and Cynophobia that is actively recruiting participants, run by University of South Florida. The registered enrollment target is 30 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06302868, a NA study of Arachnophobia and Cynophobia, is actively recruiting participants, sponsored by University of South Florida.
- RECRUITING
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to assess the feasibility of conducting a randomized controlled efficacy trial comparing the delivery of exposure therapy via a telemedicine-based virtual reality clinic (Doxy.me VR) vs. standard telemental health (TMH) to adults with intense fear of dogs, snakes, and/or spiders. The secondary purpose is to preliminarily examine the efficacy of using Doxy.me VR vs. TMH in reducing phobia severity.
Primary Outcome
The Severity Measure for Specific Phobia (SMSP) is a 10-item self-report questionnaire that assesses the severity of specific phobia symptoms relative to an individual's feared stimulus. Total scores range from 0 to 4 with higher scores indicating higher phobia severity. The SMSP has excellent internal consistency, reliability, and criterion and discriminant validity.
Conditions Studied
Interventions
- BEHAVIORAL Telemedicine Exposure Therapy Using Photos and Videos
- BEHAVIORAL Telemedicine-Based Virtual Reality Exposure Therapy
Study Locations (1)
Florida
- University of South Florida - Tampa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2023-10-03 |
| Est. Completion | 2024-08-01 |
| Phase | NA |
What NCT06302868 shows while recruiting
NCT06302868 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 3 conditions, with Arachnophobia appearing as the primary indexed condition, and to 2 interventions - of which Telemedicine Exposure Therapy Using Photos and Videos is the first listed.
NCT06302868 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT06302868 about?
NCT06302868 is a clinical study titled "Telemedicine-Based Virtual Reality Clinic for the Treatment of Phobias". The purpose of this study is to assess the feasibility of conducting a randomized controlled efficacy trial comparing the delivery of exposure therapy via a telemedicine-based virtual reality clinic (Doxy.me VR) vs. standard telemental health (TMH) to adults with intense fear of dogs, snakes, and/or...
What is the current status of trial NCT06302868?
This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2023-10-03. Estimated completion is 2024-08-01.
What conditions does trial NCT06302868 study?
This clinical trial studies the following conditions: Arachnophobia, Cynophobia, Ophidiophobia.
What interventions are being tested in trial NCT06302868?
The interventions under investigation include: Telemedicine Exposure Therapy Using Photos and Videos (BEHAVIORAL), Telemedicine-Based Virtual Reality Exposure Therapy (BEHAVIORAL).
Who is sponsoring clinical trial NCT06302868?
This trial is sponsored by University of South Florida, which has 252 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06302868 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Arachnophobia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06302868's enrollment target sits among peer trials
30 1593rd of 2000 higher than 299 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI